200 related articles for article (PubMed ID: 18402650)
41. [Gastrointestinal motility disorders and drugs: opioids, calcium antagonists, nitrates, peptides, prostaglandins and 5-hydroxytryptaminergic drugs (part II)].
Jovanović-Mićić D; Samardzić R; Beleslin B
Srp Arh Celok Lek; 1994; 122(3-4):88-92. PubMed ID: 17972818
[TBL] [Abstract][Full Text] [Related]
42. Can open-source R&D reinvigorate drug research?
Munos B
Nat Rev Drug Discov; 2006 Sep; 5(9):723-9. PubMed ID: 16915233
[TBL] [Abstract][Full Text] [Related]
43. Scales as outcome measures for Alzheimer's disease.
Black R; Greenberg B; Ryan JM; Posner H; Seeburger J; Amatniek J; Resnick M; Mohs R; Miller DS; Saumier D; Carrillo MC; Stern Y
Alzheimers Dement; 2009 Jul; 5(4):324-39. PubMed ID: 19560103
[TBL] [Abstract][Full Text] [Related]
44. Identification of drugs that interact with herbs in drug development.
Zhou SF; Zhou ZW; Li CG; Chen X; Yu X; Xue CC; Herington A
Drug Discov Today; 2007 Aug; 12(15-16):664-73. PubMed ID: 17706549
[TBL] [Abstract][Full Text] [Related]
45. Advancing Alzheimer's disease drug review as a national priority.
Perry DP
Alzheimers Dement; 2009 Mar; 5(2):180-1. PubMed ID: 19328455
[TBL] [Abstract][Full Text] [Related]
46. Prevalence of functional gastrointestinal disorders in patients with fibromyalgia and the role of psychologic distress.
Almansa C; Rey E; Sánchez RG; Sánchez AA; Díaz-Rubio M
Clin Gastroenterol Hepatol; 2009 Apr; 7(4):438-45. PubMed ID: 19138763
[TBL] [Abstract][Full Text] [Related]
47. Clinical trial design and consequences for drug development for community-acquired pneumonia: an industry perspective.
Tillotson GS; Echols RM
Clin Infect Dis; 2008 Dec; 47 Suppl 3():S237-40. PubMed ID: 18986296
[TBL] [Abstract][Full Text] [Related]
48. The challenge of cross-cultural, multi-national research: potential benefits in the functional gastrointestinal disorders.
Sperber AD
Neurogastroenterol Motil; 2009 Apr; 21(4):351-60. PubMed ID: 19309414
[TBL] [Abstract][Full Text] [Related]
49. Use of oral erythromycin for the treatment of gastrointestinal dysmotility in preterm infants.
Ng PC
Neonatology; 2009; 95(2):97-104. PubMed ID: 19218823
[TBL] [Abstract][Full Text] [Related]
50. Successful gastrointestinal cancer drug development.
Hecht JR
Semin Oncol; 2006 Dec; 33(6 Suppl 11):S24-7. PubMed ID: 17178281
[TBL] [Abstract][Full Text] [Related]
51. Trends in disease focus of drug development.
Karlberg JP
Nat Rev Drug Discov; 2008 Aug; 7(8):639-40. PubMed ID: 18670429
[No Abstract] [Full Text] [Related]
52. Mechanisms of disease: genetics of functional gastrointestinal disorders--searching the genes that matter.
Adam B; Liebregts T; Holtmann G
Nat Clin Pract Gastroenterol Hepatol; 2007 Feb; 4(2):102-10. PubMed ID: 17268545
[TBL] [Abstract][Full Text] [Related]
53. Implications of pharmacogenomics for drug development.
Kirk RJ; Hung JL; Horner SR; Perez JT
Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536
[TBL] [Abstract][Full Text] [Related]
54. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
55. Two decades of orphan product development.
Haffner ME; Whitley J; Moses M
Nat Rev Drug Discov; 2002 Oct; 1(10):821-5. PubMed ID: 12360259
[TBL] [Abstract][Full Text] [Related]
56. Modelling of the blood-brain barrier in drug discovery and development.
Cecchelli R; Berezowski V; Lundquist S; Culot M; Renftel M; Dehouck MP; Fenart L
Nat Rev Drug Discov; 2007 Aug; 6(8):650-61. PubMed ID: 17667956
[TBL] [Abstract][Full Text] [Related]
57. Improved early clinical development through human microdosing studies.
Wilding IR; Bell JA
Drug Discov Today; 2005 Jul; 10(13):890-4. PubMed ID: 15993808
[No Abstract] [Full Text] [Related]
58. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
59. [The use of prokinetics for the correction of motor and tonic digestive disorders].
Maev IV; Samsonov AA; Karmanova EA; Ivanchenko EA
Klin Med (Mosk); 2009; 87(3):49-53. PubMed ID: 19469257
[TBL] [Abstract][Full Text] [Related]
60. Use of Evidence-Based Herbal Medicines for Patients with Functional Gastrointestinal Disorders: A Conceptional Framework for Risk-Benefit Assessment and Regulatory Approaches.
Holtmann G; Schrenk D; Madisch A; Allescher HD; Ulrich-Merzenich G; Mearin F; Larrey D; Malfertheiner P
Dig Dis; 2020; 38(4):269-279. PubMed ID: 31770769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
